medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 2

<< Back Next >>

Ann Hepatol 2014; 13 (2)

Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico

Fernández-Lainez C, Ibarra-González I, Belmont-Martínez L, Monroy-Santoyo S, Guillén-López S, Vela-Amieva M

Language: English
References: 34
Page: 265-272
PDF size: 195.93 Kb.


ABSTRACT

Introduction. Hepatorenal tyrosinemia (HT1) is a treatable, inherited, metabolic disease characterized by progressive liver failure with pronounced coagulopathy. The aim of this study is to describe the clinical, biochemical, and histopathological findings in a group of Mexican HT1 patients and their outcome. Material and methods. Medical records of HT1 patients diagnosed between 1995 and 2011 were analyzed. The diagnosis of HT1 was confirmed by detection of succinylacetone in urine or blood. Results. Sixteen nonrelated HT1 cases were analyzed. Mean age at clinical onset was 9 months, and the mean age at diagnosis was 16.3 months. Main clinical findings were hepatomegaly, splenomegaly, cirrhosis, liver failure, tubulopathy, nephromegaly, Fanconi syndrome, seizures and failure to thrive. Histopathological findings were cirrhosis, fibrosis and steatosis. The HT1 group had a mortality rate of 78%. Patients who received supportive care or nutritional treatment had a 3-year survival rate of 10%. For those who underwent liver transplantation, the 6-year survival rate was 60%. In most cases pharmacological treatment with nitisinone and special dietary products were not available. The leading causes of death were fulminant liver failure, metastatic hepatocellular carcinoma, and porphyria-like neurologic crisis. Newborn screening programs in combination with the availability of orphan drugs, proper monitoring, genetic counseling, and clinical practice guidelines are needed to enable physicians to identify the disease, delay its progression, and improve patients’ quality of life. Conclusion. The devastating natural history of HT1 is still observed in Mexican patients because they are not diagnosed and treated during the early stages of the disease.


REFERENCES

  1. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertirosinemia. In: Scriver CR, Beaudet AL, Valle D (eds.). The Metabolic and Molecular Basis of Inherited Disease. Volume II. 8th ed. New York: McGraw-Hill; 2001, p. 1777-805.

  2. Held PK. Disorders of tyrosine catabolism. Mol Genet Metab 2006; 88: 103-6.

  3. Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol 2001; 4: 212-21.

  4. Nakamura K, Tanaka Y, Mitsubuchi H, Endo F. Animal models of tyrosinemia. J Nutr 2007; 137: 1556S-1560S.

  5. Bliksrud YT, Ellingsen A, Bjørås M. Fumarylacetoacetate inhibits the initial step of the base excision repair pathway: implication for the pathogenesis of tyrosinemia type I. J Inherit Metab Dis 2012. DOI 10.1007/s10545- 012-9556-0.

  6. Mak CM, Lam CW, Chim S, Siu TS, Ng KF, Tam S. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong. Clin Biochem 2013; 46: 155-9.

  7. Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 2013; 36: 15-20.

  8. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, Berger R, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994; 20: 1187-91.

  9. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010; 375: 924-37.

  10. Kitagawa T. Hepatorenal tyrosinemia. Proc Jpn Acad Ser B Phys Biol Sci 2012; 88: 192-200.

  11. Al-Dirbashi OY, Rashed MS, Jacob M, Al-Ahaideb LY, Al- Amoudi M, Rahbeeni Z, Al-Sayed MM, et al. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS. Biomed Chromatogr 2008; 22: 1181-5.

  12. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000; 4: 805-14.

  13. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006; 66: 743-50.

  14. Arnon R, Annunziato R, Miloh T, Wasserstein M, Sogawa H, Wilson M, Suchy F, et al. Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database. Pediatr Transplant 2011; 15: 400-5.

  15. Morán-Vázquez JO, Sánchez-Corona J, Pérez-Molina J, Viruete-Alcaraz M, Venegas-Mecina R. Chronic hereditary Tyrosinemia. Bol Med Hosp Infant Mex 1987; 44: 540-5 [article in Spanish].

  16. Gutiérrez-Camacho C, Villalpando-Carrión S, Escobar- Sánchez MA, Valadez-Reyes T. Tyrosinemia type I and Fanconi syndrome. Bol Med Hosp Infant Mex 2007; 64: 182-191 [article in Spanish].

  17. Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz- Echevarría L Manzanares J, Bueno MA, et al. Tyrosinemia type 1 in Spain: mutational analysis, treatment and longterm outcome. Pediatr Int 2011; 53: 985-9.

  18. Raimann E, Cornejo V, Arias C, Cabello JF, Castro G, Fernández E, de la Parra A. Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC). Rev Med Chil 2012; 140(2): 169-75 [article in Spanish].

  19. El-Karaksy H, Fahmy M, El-Raziky M, El-Koofy N, El-Sayed R, Rashed MS, El-Kiki H, et al. Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases. World J Pediatr 2011; 7: 224-31.

  20. Watson AS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Newborn screening: toward a uniform panel and system. Executive summary. Genet Med 2006; 8: S1-S11.

  21. Fernández-Lainez C, Aguilar-Lemus JJ, Vela-Amieva M, Ibarra- González I. Tandem mass spectrometry newborn screening for inborn errors of intermediary metabolism: abnormal profile interpretation. Curr Med Chem 2012; 19: 4511-22.

  22. Scott CR. The genetic tyrosinemias. Am J Med Genet Part C Semin Med Genet 142C: 121-6.

  23. Yu JS, Walker-Smith JA, Burnard ED. Neonatal hepatitis in premature infants simulating hereditary tyrosinosis. Arch Dis Child 1971; 46: 306-10.

  24. Halvorsen S, Pande H, Loken AC, Gjessing LR. Tyrosinosis. A study of 6 cases. Arch Dis Childh 1966; 41: 238-49.

  25. Dehner LP, Snover DC, Sharp HL, Ascher N, Nakhleh R, Day D. Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver. Hum Pathol 1989; 20: 149-58.

  26. Russo, S. O’Regan. Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet 1990; 47: 317-24.

  27. Chakrapani A, Holme E. Disorders of Tyrosine metabolism. In: Fernandes J, Saudubray JM, Van den Berghe G, Walter JH (eds.). Inborn Metabolic Diseases diagnosis and treatment. 4th ed. Heidelberg: Springer; 2006, p. 233-43.

  28. Allard P, Grenier A, Korson MS, Zytkovicz TH. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004; 37: 1010-5.

  29. Varela-Fascinetto G, Dávila-Pérez R, Nieto-Zermeño J, Bracho-Blanchet E, Fuentes-García V, Castañeda-Martínez P, Abarca-García MA, et al. Experience of a successful pediatric liver transplant program in Mexico. Transplant Proc 2005; 37: 1201-2.

  30. Varela-Fascinetto G, Hernández-Plata JA, Nieto-Zermeño J, Alcántar-Fierros JM, Fuentes-García V, Castañeda-Martínez P, Valencia-Mayoral P, et. al. Pediatric liver transplant program at Hospital Infantil de Mexico Federico Gomez. Rev Invest Clin 2011; 63(Suppl. 1): 57-61 [article in Spanish].

  31. Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab 2012; 107: 49-54.

  32. Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 2005; 28: 871-6.

  33. van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro-methylbenzoyl)-1, 3- cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005; 40: 90-3.

  34. Herzog D, Martin S, Turpin S, Alvarez F. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006; 81: 672-7.




2020     |     www.medigraphic.com